Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127607 | 0.91 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL1171367 | 0.91 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL6567420 | 0.88 | SLC6A9 (0.93) | SLC6A9 | |
| SCHEMBL6828424 | 0.86 | SLC6A9 (0.86) | SLC6A9 | |
| SCHEMBL6823223 | 0.86 | SLC6A9 (0.89) | SLC6A9 | |
| SCHEMBL6013413 | 0.85 | SLC6A9 (0.80) | SLC6A9 | |
| SCHEMBL6254425 | 0.83 | SLC6A9 (0.85) | SLC6A9 | |
| SCHEMBL13780465 | 0.83 | SLC6A9 (0.77) | SLC6A9 | |
| Oxalic Acid SCHEMBL7317614 | 0.83 | SLC6A4 (0.88) | SLC6A9 | |
| SCHEMBL10076387 | 0.83 | SLC6A4 (0.79) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4531854-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119584967-A | Compositions and methods for treating hepatic porphyria with glycine transport inhibitors | 迪斯克医药公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240390362-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | DISC MEDICINE, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118319914-A | Compositions and methods for treating anemia associated with ribosomal disorders | 迪斯克医药公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118319913-A | Compositions and methods for treating polycythemia | 迪斯克医药公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4304597-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | Disc Medicine, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023235326-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-115279372-A | Methods of treating erythropoietic protoporphyrinopathy, X-linked protoporphyrinopathy or congenital erythropoietic porphyrias with glycine transporter inhibitors | 迪斯克医药公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-110325181-B | Treatment of alcohol use disorders | B·苏得庞穆 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022192731-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | DISC MEDICINE, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11318143-B2 | Treatment of alcohol use disorder | SOEDERPALM BO (SE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390362-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | PRCP, PAXBP1, PPOX | SLC6A9 2842/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.